164 related articles for article (PubMed ID: 37137949)
21. Prognostic significance of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with metastatic gastric cancer.
Zhao G; Liu N; Wang S; Guo J; Song X; Qi Y; Qiu W; Lv J
Medicine (Baltimore); 2020 Mar; 99(10):e19405. PubMed ID: 32150090
[TBL] [Abstract][Full Text] [Related]
22. Lymphocyte-to-C-Reactive Protein Ratio Is the Most Sensitive Inflammation-Based Prognostic Score in Patients With Unresectable Metastatic Colorectal Cancer.
Nakamura Y; Shida D; Boku N; Yoshida T; Tanabe T; Takamizawa Y; Takashima A; Kanemitsu Y
Dis Colon Rectum; 2021 Nov; 64(11):1331-1341. PubMed ID: 34623347
[TBL] [Abstract][Full Text] [Related]
23. The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE.
Lu LH; Wei W; Li SH; Zhang YF; Guo RP
Aging (Albany NY); 2021 Feb; 13(4):5358-5368. PubMed ID: 33589570
[TBL] [Abstract][Full Text] [Related]
24. Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8
Miyazaki K; Morine Y; Imura S; Ikemoto T; Saito Y; Yamada S; Tokuda K; Okikawa S; Yamashita S; Oya T; Tsuneyama K; Shimada M
Surg Today; 2021 Dec; 51(12):1985-1995. PubMed ID: 34009433
[TBL] [Abstract][Full Text] [Related]
25. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
Song A; Eo W; Lee S
World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
[TBL] [Abstract][Full Text] [Related]
26. Preoperative lymphocyte to C-reactive protein ratio: A new prognostic indicator of post-primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
Liu Y; Ye T; Chen L; Xu B; Wu G; Zong G
Int Immunopharmacol; 2023 Jan; 114():109594. PubMed ID: 36525793
[TBL] [Abstract][Full Text] [Related]
27. Lymphocyte-to-C-reactive protein ratio is a potential new prognostic biomarker for patients with lung cancer.
He Y; Gong R; Peng KW; Liu LZ; Sun LY; Wang HY
Biomark Med; 2020 Jun; 14(9):717-726. PubMed ID: 32643402
[No Abstract] [Full Text] [Related]
28. The preoperative neutrophil to lymphocyte ratio is a superior indicator of prognosis compared with other inflammatory biomarkers in resectable colorectal cancer.
Song Y; Yang Y; Gao P; Chen X; Yu D; Xu Y; Zhao J; Wang Z
BMC Cancer; 2017 Nov; 17(1):744. PubMed ID: 29126400
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of preoperative neutrophil-to-lymphocyte ratio in papillary renal cell carcinoma patients after receiving curative surgery based on a retrospective cohort.
Zhang Z; Yu Y; Zheng J; Zhang M; Niu H
BMC Urol; 2021 Mar; 21(1):43. PubMed ID: 33752642
[TBL] [Abstract][Full Text] [Related]
30. Association of nutritional risk and systemic inflammation with survival in patients with colorectal cancer who underwent curative surgery.
Nakamura Y; Imada A; Fukugaki A; Kanto S; Yamaura T; Kinjo Y; Kuroda N
Clin Nutr ESPEN; 2022 Jun; 49():417-424. PubMed ID: 35623847
[TBL] [Abstract][Full Text] [Related]
31. Lymphocyte-C-reactive protein ratio as a prognostic marker associated with the tumor immune microenvironment in intrahepatic cholangiocarcinoma.
Yugawa K; Itoh S; Yoshizumi T; Morinaga A; Iseda N; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
Int J Clin Oncol; 2021 Oct; 26(10):1901-1910. PubMed ID: 34117554
[TBL] [Abstract][Full Text] [Related]
32. Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma.
Iseda N; Itoh S; Yoshizumi T; Tomiyama T; Morinaga A; Shimagaki T; Wang H; Kurihara T; Toshima T; Nagao Y; Harada N; Oda Y; Mori M
Int J Clin Oncol; 2021 Oct; 26(10):1890-1900. PubMed ID: 34251555
[TBL] [Abstract][Full Text] [Related]
33. The prognostic impact of the lymphocyte-to-C-reactive protein ratio in patients with unresectable or recurrent advanced gastric cancer treated with first- and second-line treatment.
Matsunaga T; Saito H; Fukumoto Y; Kuroda H; Taniguchi K; Takahashi S; Osaki T; Iwamoto A; Fukuda K; Shimizu S; Shishido Y; Miyatani K; Fujiwara Y
Surg Today; 2023 Aug; 53(8):940-948. PubMed ID: 36595075
[TBL] [Abstract][Full Text] [Related]
34. [Lymphocyte-to-C-reactive protein ratio in COVID-19: an unexplored tool].
Gandino IJ; Padilla MJ; Carreras M; Caballero V; López Griskan S; Carlos J; Ametla Y; Borodowski H; Ladelfa J; Themines S; Basta MC; Presas JL
Medicina (B Aires); 2022; 82(5):689-694. PubMed ID: 36220025
[TBL] [Abstract][Full Text] [Related]
35. Lymphocyte to C-reactive protein ratio predicts long-term outcomes for patients with lower rectal cancer.
Nishi M; Shimada M; Tokunaga T; Higashijima J; Yoshikawa K; Kashihara H; Takasu C; Ishikawa D; Wada Y; Eto S; Yoshimoto T
World J Surg Oncol; 2021 Jul; 19(1):201. PubMed ID: 34229704
[TBL] [Abstract][Full Text] [Related]
36. Mid-arm and calf circumferences are stronger mortality predictors than body mass index for patients with chronic obstructive pulmonary disease.
Ho SC; Wang JY; Kuo HP; Huang CD; Lee KY; Chuang HC; Feng PH; Chen TT; Hsu MF
Int J Chron Obstruct Pulmon Dis; 2016; 11():2075-80. PubMed ID: 27621613
[TBL] [Abstract][Full Text] [Related]
37. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer.
Liu Y; Chen S; Zheng C; Ding M; Zhang L; Wang L; Xie M; Zhou J
BMC Cancer; 2017 Apr; 17(1):285. PubMed ID: 28431566
[TBL] [Abstract][Full Text] [Related]
38. Lymphocyte-to-C-Reactive Protein Ratio as a Novel Marker for Predicting Oncological Outcomes in Patients with Esophageal Cancer.
Takeuchi M; Kawakubo H; Hoshino S; Matsuda S; Mayanagi S; Irino T; Fukuda K; Nakamura R; Wada N; Kitagawa Y
World J Surg; 2021 Nov; 45(11):3370-3377. PubMed ID: 34383091
[TBL] [Abstract][Full Text] [Related]
39. Novel Signatures Based on the Lymphocyte-to-C-Reactive Protein Ratio Predict the Prognosis of Patients with Early Breast Cancer: A Retrospective Study.
Wang L; Zhang YL; Jiang C; Duan FF; Yuan ZY; Huang JJ; Bi XW
J Inflamm Res; 2022; 15():3957-3974. PubMed ID: 35860229
[TBL] [Abstract][Full Text] [Related]
40. Preoperative lymphocyte to C-reactive protein ratio as a new prognostic indicator in patients with resectable gallbladder cancer.
Yao WY; Wu XS; Liu SL; Wu ZY; Dong P; Gong W
Hepatobiliary Pancreat Dis Int; 2022 Jun; 21(3):267-272. PubMed ID: 34507896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
